Now Covered by Most Payers

Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine 0.6 mg Capsules Are Covered by More Than 90% of Plans*

Due to recent formulary changes, patients covered by Medicare, Medicaid and many major commercial insurance plans should have more access and coverage for their Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules prescriptions.

Click on our announcements below to find out more about each coverage update.

*Managed Markets Insight & Technology, LLC database and formulary status as of January 2021.

Recent Announcements

All the following are Effective January 1, 2021
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the Humana MEDICARE Part D formulary and Humana Commercial formulary.
Details: Colcrys® (colchicine, USP) 0.6 mg tablets, colchicine tablets, and colchicine capsules require prior authorization on the Humana MEDICARE Part D formulary.

Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the CVS SilverScript® MEDICARE Part D formulary.
Details: Colcrys® (colchicine, USP) 0.6 mg tablets and colchicine capsules require prior authorization on the CVS SilverScript® MEDICARE Part D formulary.

Mitigare® (Colchicine) 0.6 mg Capsules are now a Preferred Agent on the Cigna MEDICARE Part D formulary.

Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the BCBS-AZ Blue Medicare RX formulary.

Mitigare® (Colchicine) 0.6 mg Capsules are now a Preferred on Wisconsin Medicaid Formulary.
Details: Colcrys® (colchicine, USP) 0.6 mg tablets, colchicine tablets, and colchicine capsules require prior authorization on Wisconsin Medicaid Formulary.

Mitigare® (Colchicine) 0.6 mg Capsules are now a Preferred Agent on the Aetna MEDICARE Part D formulary.

 

Colcrys® is a registered trademark of Takeda Pharmaceuticals America, Inc.

Inventory Alert

Don’t forget to replenish your inventory of Mitigare® and Authorized Generic Colchicine 0.6 mg Capsules. Visit our Pharmacist Information page to learn more about Mitigare® and our co-pay savings program, True Blue Savings.

 

Mitigare (Colchicine) 0.6 mg Capsules

ProductNDC#Bottle
Mitigare® 0.6 mg Capsules59467-318-3030 ct
Mitigare® 0.6 mg Capsules59467-318-01100 ct
Mitigare® 0.6 mg Capsules59467-318-101,000 ct

Authorized Generic Colchicine 0.6 mg Capsules

ProductNDC#Bottle
Colchicine 0.6 mg Capsules0143-3018-3030 ct
Colchicine 0.6 mg Capsules0143-3018-01100 ct
Colchicine 0.6 mg Capsules0143-3018-101,000 ct

Mitigare® Pharmacy Sell Sheet

Take a closer look at dispensing information for Mitigare® (Colchicine) 0.6 mg Capsules and Authorized Generic Colchicine 0.6 mg Capsules.

DOWNLOAD

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.